CN104822699B - 用于治疗肥胖症的胰高血糖素/glp-1激动剂 - Google Patents

用于治疗肥胖症的胰高血糖素/glp-1激动剂 Download PDF

Info

Publication number
CN104822699B
CN104822699B CN201380062842.3A CN201380062842A CN104822699B CN 104822699 B CN104822699 B CN 104822699B CN 201380062842 A CN201380062842 A CN 201380062842A CN 104822699 B CN104822699 B CN 104822699B
Authority
CN
China
Prior art keywords
glp
less
peptide
glucagon
agonist peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380062842.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN104822699A (zh
Inventor
B·阿格拉姆
M·安童森
M·贝德纳瑞克
N·伯迈斯特
L·班瑟姆
D·费尔曼
M·弗里齐-弗雷丁
R·杰克逊
R·J·洛夫马克
J·梅特卡夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Priority to CN201910117184.2A priority Critical patent/CN109776670A/zh
Publication of CN104822699A publication Critical patent/CN104822699A/zh
Application granted granted Critical
Publication of CN104822699B publication Critical patent/CN104822699B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CN201380062842.3A 2012-12-11 2013-12-10 用于治疗肥胖症的胰高血糖素/glp-1激动剂 Active CN104822699B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910117184.2A CN109776670A (zh) 2012-12-11 2013-12-10 用于治疗肥胖症的胰高血糖素/glp-1激动剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261735823P 2012-12-11 2012-12-11
US61/735,823 2012-12-11
PCT/IB2013/003191 WO2014091316A2 (en) 2012-12-11 2013-12-10 Glucagon/glp-1 agonists for the treatment of obesity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910117184.2A Division CN109776670A (zh) 2012-12-11 2013-12-10 用于治疗肥胖症的胰高血糖素/glp-1激动剂

Publications (2)

Publication Number Publication Date
CN104822699A CN104822699A (zh) 2015-08-05
CN104822699B true CN104822699B (zh) 2019-03-01

Family

ID=50588751

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380062842.3A Active CN104822699B (zh) 2012-12-11 2013-12-10 用于治疗肥胖症的胰高血糖素/glp-1激动剂
CN201910117184.2A Pending CN109776670A (zh) 2012-12-11 2013-12-10 用于治疗肥胖症的胰高血糖素/glp-1激动剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910117184.2A Pending CN109776670A (zh) 2012-12-11 2013-12-10 用于治疗肥胖症的胰高血糖素/glp-1激动剂

Country Status (26)

Country Link
US (4) US9765130B2 (cg-RX-API-DMAC7.html)
EP (2) EP2931745B1 (cg-RX-API-DMAC7.html)
JP (1) JP6490011B2 (cg-RX-API-DMAC7.html)
KR (1) KR102080366B1 (cg-RX-API-DMAC7.html)
CN (2) CN104822699B (cg-RX-API-DMAC7.html)
AR (1) AR093903A1 (cg-RX-API-DMAC7.html)
AU (3) AU2013356934C1 (cg-RX-API-DMAC7.html)
BR (1) BR112015012238B1 (cg-RX-API-DMAC7.html)
CA (1) CA2893445C (cg-RX-API-DMAC7.html)
CY (2) CY1121114T1 (cg-RX-API-DMAC7.html)
DK (2) DK2931745T3 (cg-RX-API-DMAC7.html)
ES (2) ES2698329T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20220734T1 (cg-RX-API-DMAC7.html)
HU (1) HUE039952T2 (cg-RX-API-DMAC7.html)
LT (2) LT3495380T (cg-RX-API-DMAC7.html)
MX (2) MX365458B (cg-RX-API-DMAC7.html)
PL (2) PL2931745T3 (cg-RX-API-DMAC7.html)
PT (2) PT3495380T (cg-RX-API-DMAC7.html)
RS (2) RS63305B1 (cg-RX-API-DMAC7.html)
RU (2) RU2018137842A (cg-RX-API-DMAC7.html)
SG (2) SG11201503230XA (cg-RX-API-DMAC7.html)
SI (2) SI3495380T1 (cg-RX-API-DMAC7.html)
SM (2) SMT201800611T1 (cg-RX-API-DMAC7.html)
TR (1) TR201815172T4 (cg-RX-API-DMAC7.html)
TW (2) TWI617574B (cg-RX-API-DMAC7.html)
WO (1) WO2014091316A2 (cg-RX-API-DMAC7.html)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) * 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
CA2902352A1 (en) * 2013-03-14 2014-09-18 Medimmune Limited Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重glp-1/升糖素受體促效劑
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN106519015B (zh) * 2014-09-23 2020-04-17 深圳市图微安创科技开发有限公司 胃泌酸调节素类似物
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
CN117106085A (zh) * 2015-12-23 2023-11-24 美国安进公司 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法
CN106938050B (zh) * 2015-12-29 2021-08-24 派格生物医药(苏州)股份有限公司 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途
SG10202109721PA (en) * 2016-03-10 2021-10-28 Medimmune Ltd Glucagon and glp-1 co-agonists for the treatment of obesity
US20190388510A1 (en) * 2016-06-02 2019-12-26 Indiana University Research And Technology Corporation Glucagon-t3 conjugates
CN107281471A (zh) * 2017-06-26 2017-10-24 中国药科大学 一种改构的胰高血糖素样肽-1及其修饰物的应用
US11419918B2 (en) * 2017-11-06 2022-08-23 Shenzhen Turier Biotech Co., Ltd. Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide
TWI770085B (zh) * 2017-11-21 2022-07-11 日商武田藥品工業股份有限公司 胜肽化合物
SMT202200352T1 (it) 2018-04-05 2022-09-14 Sun Pharmaceutical Ind Ltd Analoghi del glp-1 innovativi
US12257287B2 (en) 2018-11-12 2025-03-25 Tianjin Institute Of Pharmaceutical Research Co., Ltd. Glucagon-derived peptide and use thereof
CA3139613A1 (en) 2019-05-21 2020-11-26 Medimmune Limited Cyclodextrin based injectable coformulations of sglt2 inhibitors and incretin peptides
MX2021015930A (es) 2019-07-01 2022-02-03 Medimmune Ltd Composiciones farmaceuticas para peptidos co-agonistas de glucagon y glp-1.
CN112898406B (zh) * 2019-10-12 2023-11-10 深圳纳福生物医药有限公司 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
EP4069720A4 (en) * 2019-12-03 2023-12-27 MedImmune, LLC COMBINATION THERAPY WITH GLUCAGON AND GLP-1 CO-AGONISTS FOR THE TREATMENT OF OBESITY
TW202140061A (zh) 2020-01-10 2021-11-01 英商梅迪繆思有限公司 用於治療2型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及glp-1協同促效劑
CN113493503B (zh) * 2020-04-08 2022-08-05 浙江道尔生物科技有限公司 一种肠促胰岛素类似物及其制备方法和用途
CN120737188A (zh) 2020-04-24 2025-10-03 勃林格殷格翰国际有限公司 作为长效glp-1/升糖素受体激动剂以治疗脂肪肝疾病及脂肪肝炎的升糖素类似物
TW202313974A (zh) 2021-06-08 2023-04-01 瑞典商阿斯特捷利康公司 用於治療肝病之組合療法
KR20240043778A (ko) 2021-07-30 2024-04-03 베링거 인겔하임 인터내셔날 게엠베하 장시간-작용하는 glp1/글루카곤 수용체 작용제를 위한 용량 용법
TW202346323A (zh) 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的glp—1及升糖素雙重激動肽
US20240148833A1 (en) * 2022-11-03 2024-05-09 EFIL BioScience Inc. Composition comprising glp-1 receptor agonist and acat inhibitor
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
CN115975057B (zh) * 2023-03-16 2023-05-16 杭州信海医药科技有限公司 一种可妥度肽的固相合成方法
EP4724472A2 (en) 2023-06-09 2026-04-15 Sun Pharmaceutical Industries Limited Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
WO2025024788A1 (en) * 2023-07-27 2025-01-30 Biomedit, Llc Stabilized glp-1 peptides and dual agonist peptides against glp-1r and gipr and methods of use thereof
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
AU2024408289A1 (en) 2023-12-22 2026-08-06 Tangram Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity
US20260091086A1 (en) 2024-05-20 2026-04-02 Medimmune Limited Polypeptide combinations and uses thereof
CN118787658B (zh) * 2024-06-14 2025-01-21 中国农业大学 一种胰高血糖素样肽-1受体特异性核酸适配体在代谢疾病干预中的应用
WO2026058194A1 (en) 2024-09-12 2026-03-19 Medimmune Limited Polypeptide dosage regimens
WO2026093970A1 (en) 2024-11-01 2026-05-07 Medimmune Limited Combination dosage regimens of amylin receptor agonists and glp-1 receptor agonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022004A2 (en) * 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
CN1935846A (zh) * 2005-09-14 2007-03-28 王庆华 一种用于治疗糖尿病的融合蛋白及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30326A (en) * 1860-10-09 Steam-g-eneratob
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
CN1938334A (zh) * 2004-01-30 2007-03-28 瓦拉塔药品公司 Glp-1激动剂和胃泌素化合物的联合使用
DE102004043153B4 (de) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
MX2008002028A (es) * 2005-08-11 2008-03-27 Amylin Pharmaceuticals Inc Polipeptidos hibridos con propiedades de seleccion.
US8563521B2 (en) 2007-06-21 2013-10-22 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
WO2009058734A1 (en) * 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
ES2661228T3 (es) * 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
TWI617574B (zh) * 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022004A2 (en) * 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
CN1935846A (zh) * 2005-09-14 2007-03-28 王庆华 一种用于治疗糖尿病的融合蛋白及其制备方法和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Glucagon and Glucagon-like Peptide 1: Selective Receptor Recognition via Distinct Peptide Epitopes;Hjorth.S.A等;《The Journal of Biological Chemistry》;19940101;第269卷(第48期);摘要,表1 *

Also Published As

Publication number Publication date
PL3495380T3 (pl) 2022-08-01
US11230584B2 (en) 2022-01-25
WO2014091316A2 (en) 2014-06-19
EP3495380A1 (en) 2019-06-12
SG10201801159WA (en) 2018-03-28
HRP20220734T1 (hr) 2022-09-02
TWI617574B (zh) 2018-03-11
SMT201800611T1 (it) 2019-01-11
JP6490011B2 (ja) 2019-03-27
TW201829452A (zh) 2018-08-16
TW201427993A (zh) 2014-07-16
MX2015006568A (es) 2015-08-05
WO2014091316A3 (en) 2014-10-30
LT3495380T (lt) 2022-06-27
AU2017261505A1 (en) 2017-12-07
EP3495380B1 (en) 2022-03-30
BR112015012238B1 (pt) 2022-03-29
KR102080366B1 (ko) 2020-02-21
AU2017261505B2 (en) 2019-10-10
JP2016501256A (ja) 2016-01-18
CN109776670A (zh) 2019-05-21
AU2019272054A1 (en) 2020-01-02
US20220098265A1 (en) 2022-03-31
US20170342121A1 (en) 2017-11-30
BR112015012238A2 (cg-RX-API-DMAC7.html) 2017-08-15
MX365458B (es) 2019-06-04
RU2018137842A3 (cg-RX-API-DMAC7.html) 2022-04-01
TR201815172T4 (tr) 2018-11-21
MX2019006260A (es) 2019-08-14
PT3495380T (pt) 2022-06-28
HK1216179A1 (en) 2016-10-21
CA2893445A1 (en) 2014-06-19
SI2931745T1 (sl) 2018-11-30
CY1125302T1 (el) 2025-03-28
PL2931745T3 (pl) 2019-04-30
SMT202200266T1 (it) 2022-07-21
AU2013356934A1 (en) 2015-05-21
US9765130B2 (en) 2017-09-19
US20150307579A1 (en) 2015-10-29
ES2926713T3 (es) 2022-10-27
RU2018137842A (ru) 2018-12-13
RU2671088C2 (ru) 2018-10-29
EP2931745B1 (en) 2018-08-22
SG11201503230XA (en) 2015-06-29
RU2015127780A (ru) 2017-01-19
TWI674270B (zh) 2019-10-11
LT2931745T (lt) 2018-11-12
AU2013356934B2 (en) 2017-08-17
KR20150093167A (ko) 2015-08-17
CA2893445C (en) 2020-06-02
HRP20181678T1 (hr) 2019-03-08
MX388904B (es) 2025-03-20
PT2931745T (pt) 2018-11-29
ES2698329T3 (es) 2019-02-04
EP2931745A2 (en) 2015-10-21
AU2017261505C1 (en) 2020-07-30
RS57899B1 (sr) 2019-01-31
AU2013356934C1 (en) 2018-07-05
CY1121114T1 (el) 2019-12-11
DK3495380T3 (da) 2022-06-20
US20200115431A1 (en) 2020-04-16
CN104822699A (zh) 2015-08-05
RS63305B1 (sr) 2022-07-29
AR093903A1 (es) 2015-06-24
DK2931745T3 (en) 2018-12-10
SI3495380T1 (sl) 2022-08-31
HUE039952T2 (hu) 2019-02-28
US10556939B2 (en) 2020-02-11

Similar Documents

Publication Publication Date Title
CN109776670A (zh) 用于治疗肥胖症的胰高血糖素/glp-1激动剂
JP5887335B2 (ja) 新規ペプチドならびにそれらを調製および使用するための方法
US9714277B2 (en) Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity
KR102460198B1 (ko) 비만 치료를 위한 글루카곤 및 glp-1 공동-작용제
CN103649127A (zh) 用于代谢病症和疾病治疗的组合物、应用和方法
WO2017197048A1 (en) Albumin binding conjugate compositions and methods of making and using same
WO2008018600A1 (fr) AGENT THÉRAPEUTIQUE PERMETTANT D'ACCÉLÉRER LA RÉPARATION DES NERFS RACHIDIENS COMPRENANT EN TANT QUE MATIÈRE ACTIVE DE LA GHRÉLINE, UN DÉRIVÉ DE CELLE-CI OU UNE SUBSTANCE CAPABLE D'AGIR SUR LE GHS-R1a
CN120607604A (zh) 改进的三靶点激动剂
HK40010017B (en) Glucagon and glp-1 co-agonists for the treatment of obesity
BR122017013755A2 (pt) peptideos agonistas de glucagon/glp-1, composição farmaceutica, kit e uso compreendendo tais peptídeos
HK1216179B (en) Glucagon/glp-1 agonists for the treatment of obesity

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant